Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-05, Vol.350 (22), p.2239-2246 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2246 |
|---|---|
| container_issue | 22 |
| container_start_page | 2239 |
| container_title | The New England journal of medicine |
| container_volume | 350 |
| creator | Thompson, Ian M Pauler, Donna K Goodman, Phyllis J Tangen, Catherine M Lucia, M. Scott Parnes, Howard L Minasian, Lori M Ford, Leslie G Lippman, Scott M Crawford, E. David Crowley, John J Coltman, Charles A |
| description | Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449 men (15 percent), 67 of whom had high-grade tumors.
A PSA level of 4.0 ng per milliliter or less does not rule out the presence of prostate cancer, including high-grade tumors.
When first described in 1979, prostate-specific antigen (PSA) was considered a useful marker for assessing treatment responses and follow-up among patients with prostate cancer.
1
After the publication of reports on several series in which the need for a biopsy of the prostate was based on the results of PSA tests, the potential of the PSA level as a screening tool was recognized.
2
,
3
Further experience led to the consensus that a PSA level of more than 4.0 ng per milliliter had predictive value for the diagnosis of prostate cancer.
4
Disease detection subsequently increased dramatically.
5
More recent data suggest that a . . . |
| doi_str_mv | 10.1056/NEJMoa031918 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71955667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>645396691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-436360fb74cdde9b041a6dafc644e34a3585826d2cd75dcfd38705296989c703</originalsourceid><addsrcrecordid>eNpt0N1KIzEYBuAgLlqrZx5LEN2jHU0mf5NDKeru0qqg50Oa-aamZGZqMlW8BO_DK_NKNtKispiTQHi-N8mL0D4lJ5QIeXp1_nfSGcKopsUGGlDBWMY5kZtoQEheZFxpto12YpyTtCjXW2ibCiqZUmyAZjcBHo2H1gLuanwTutibHvDIpJOATdO1MzyBFj-5_h6bD5DdLsC62ll81vZulsAYHsHjt5dXfkJwGlqk8Ynz3nnXQ9hFP2rjI-yt9yG6uzi_G_3OxteXf0Zn48yKXPUZZ5JJUk8Vt1UFeko4NbIytZWcA-OGiUIUuaxyWylR2bpihSIi11IX2irChujnKnYRuoclxL5sXLTgvWmhW8ZSUS2ElCrBw__gvFuGNj2tzHOmOZWpxyH6tUI2_ToGqMtFcI0JzyUl5Xv55dfyEz9YZy6nDVSfeN12AsdrYKI1vg6pZBe_OKWp4u9BRyvXNLFsYd58f98_6syWwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223941653</pqid></control><display><type>article</type><title>Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Thompson, Ian M ; Pauler, Donna K ; Goodman, Phyllis J ; Tangen, Catherine M ; Lucia, M. Scott ; Parnes, Howard L ; Minasian, Lori M ; Ford, Leslie G ; Lippman, Scott M ; Crawford, E. David ; Crowley, John J ; Coltman, Charles A</creator><creatorcontrib>Thompson, Ian M ; Pauler, Donna K ; Goodman, Phyllis J ; Tangen, Catherine M ; Lucia, M. Scott ; Parnes, Howard L ; Minasian, Lori M ; Ford, Leslie G ; Lippman, Scott M ; Crawford, E. David ; Crowley, John J ; Coltman, Charles A</creatorcontrib><description>Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449 men (15 percent), 67 of whom had high-grade tumors.
A PSA level of 4.0 ng per milliliter or less does not rule out the presence of prostate cancer, including high-grade tumors.
When first described in 1979, prostate-specific antigen (PSA) was considered a useful marker for assessing treatment responses and follow-up among patients with prostate cancer.
1
After the publication of reports on several series in which the need for a biopsy of the prostate was based on the results of PSA tests, the potential of the PSA level as a screening tool was recognized.
2
,
3
Further experience led to the consensus that a PSA level of more than 4.0 ng per milliliter had predictive value for the diagnosis of prostate cancer.
4
Disease detection subsequently increased dramatically.
5
More recent data suggest that a . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa031918</identifier><identifier>PMID: 15163773</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Biopsy ; Clinical trials ; Finasteride - therapeutic use ; General aspects ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical diagnosis ; Medical sciences ; Men ; Middle Aged ; Nephrology. Urinary tract diseases ; Prevalence ; Prostate - pathology ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - epidemiology ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - prevention & control ; Risk ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The New England journal of medicine, 2004-05, Vol.350 (22), p.2239-2246</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-436360fb74cdde9b041a6dafc644e34a3585826d2cd75dcfd38705296989c703</citedby><cites>FETCH-LOGICAL-c527t-436360fb74cdde9b041a6dafc644e34a3585826d2cd75dcfd38705296989c703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa031918$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223941653?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52361,54043,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15791748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15163773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Ian M</creatorcontrib><creatorcontrib>Pauler, Donna K</creatorcontrib><creatorcontrib>Goodman, Phyllis J</creatorcontrib><creatorcontrib>Tangen, Catherine M</creatorcontrib><creatorcontrib>Lucia, M. Scott</creatorcontrib><creatorcontrib>Parnes, Howard L</creatorcontrib><creatorcontrib>Minasian, Lori M</creatorcontrib><creatorcontrib>Ford, Leslie G</creatorcontrib><creatorcontrib>Lippman, Scott M</creatorcontrib><creatorcontrib>Crawford, E. David</creatorcontrib><creatorcontrib>Crowley, John J</creatorcontrib><creatorcontrib>Coltman, Charles A</creatorcontrib><title>Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449 men (15 percent), 67 of whom had high-grade tumors.
A PSA level of 4.0 ng per milliliter or less does not rule out the presence of prostate cancer, including high-grade tumors.
When first described in 1979, prostate-specific antigen (PSA) was considered a useful marker for assessing treatment responses and follow-up among patients with prostate cancer.
1
After the publication of reports on several series in which the need for a biopsy of the prostate was based on the results of PSA tests, the potential of the PSA level as a screening tool was recognized.
2
,
3
Further experience led to the consensus that a PSA level of more than 4.0 ng per milliliter had predictive value for the diagnosis of prostate cancer.
4
Disease detection subsequently increased dramatically.
5
More recent data suggest that a . . .</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Clinical trials</subject><subject>Finasteride - therapeutic use</subject><subject>General aspects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical diagnosis</subject><subject>Medical sciences</subject><subject>Men</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prevalence</subject><subject>Prostate - pathology</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>Risk</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0N1KIzEYBuAgLlqrZx5LEN2jHU0mf5NDKeru0qqg50Oa-aamZGZqMlW8BO_DK_NKNtKispiTQHi-N8mL0D4lJ5QIeXp1_nfSGcKopsUGGlDBWMY5kZtoQEheZFxpto12YpyTtCjXW2ibCiqZUmyAZjcBHo2H1gLuanwTutibHvDIpJOATdO1MzyBFj-5_h6bD5DdLsC62ll81vZulsAYHsHjt5dXfkJwGlqk8Ynz3nnXQ9hFP2rjI-yt9yG6uzi_G_3OxteXf0Zn48yKXPUZZ5JJUk8Vt1UFeko4NbIytZWcA-OGiUIUuaxyWylR2bpihSIi11IX2irChujnKnYRuoclxL5sXLTgvWmhW8ZSUS2ElCrBw__gvFuGNj2tzHOmOZWpxyH6tUI2_ToGqMtFcI0JzyUl5Xv55dfyEz9YZy6nDVSfeN12AsdrYKI1vg6pZBe_OKWp4u9BRyvXNLFsYd58f98_6syWwg</recordid><startdate>20040527</startdate><enddate>20040527</enddate><creator>Thompson, Ian M</creator><creator>Pauler, Donna K</creator><creator>Goodman, Phyllis J</creator><creator>Tangen, Catherine M</creator><creator>Lucia, M. Scott</creator><creator>Parnes, Howard L</creator><creator>Minasian, Lori M</creator><creator>Ford, Leslie G</creator><creator>Lippman, Scott M</creator><creator>Crawford, E. David</creator><creator>Crowley, John J</creator><creator>Coltman, Charles A</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20040527</creationdate><title>Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter</title><author>Thompson, Ian M ; Pauler, Donna K ; Goodman, Phyllis J ; Tangen, Catherine M ; Lucia, M. Scott ; Parnes, Howard L ; Minasian, Lori M ; Ford, Leslie G ; Lippman, Scott M ; Crawford, E. David ; Crowley, John J ; Coltman, Charles A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-436360fb74cdde9b041a6dafc644e34a3585826d2cd75dcfd38705296989c703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Clinical trials</topic><topic>Finasteride - therapeutic use</topic><topic>General aspects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical diagnosis</topic><topic>Medical sciences</topic><topic>Men</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prevalence</topic><topic>Prostate - pathology</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>Risk</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Ian M</creatorcontrib><creatorcontrib>Pauler, Donna K</creatorcontrib><creatorcontrib>Goodman, Phyllis J</creatorcontrib><creatorcontrib>Tangen, Catherine M</creatorcontrib><creatorcontrib>Lucia, M. Scott</creatorcontrib><creatorcontrib>Parnes, Howard L</creatorcontrib><creatorcontrib>Minasian, Lori M</creatorcontrib><creatorcontrib>Ford, Leslie G</creatorcontrib><creatorcontrib>Lippman, Scott M</creatorcontrib><creatorcontrib>Crawford, E. David</creatorcontrib><creatorcontrib>Crowley, John J</creatorcontrib><creatorcontrib>Coltman, Charles A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Ian M</au><au>Pauler, Donna K</au><au>Goodman, Phyllis J</au><au>Tangen, Catherine M</au><au>Lucia, M. Scott</au><au>Parnes, Howard L</au><au>Minasian, Lori M</au><au>Ford, Leslie G</au><au>Lippman, Scott M</au><au>Crawford, E. David</au><au>Crowley, John J</au><au>Coltman, Charles A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-05-27</date><risdate>2004</risdate><volume>350</volume><issue>22</issue><spage>2239</spage><epage>2246</epage><pages>2239-2246</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449 men (15 percent), 67 of whom had high-grade tumors.
A PSA level of 4.0 ng per milliliter or less does not rule out the presence of prostate cancer, including high-grade tumors.
When first described in 1979, prostate-specific antigen (PSA) was considered a useful marker for assessing treatment responses and follow-up among patients with prostate cancer.
1
After the publication of reports on several series in which the need for a biopsy of the prostate was based on the results of PSA tests, the potential of the PSA level as a screening tool was recognized.
2
,
3
Further experience led to the consensus that a PSA level of more than 4.0 ng per milliliter had predictive value for the diagnosis of prostate cancer.
4
Disease detection subsequently increased dramatically.
5
More recent data suggest that a . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>15163773</pmid><doi>10.1056/NEJMoa031918</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-05, Vol.350 (22), p.2239-2246 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71955667 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Aged Aged, 80 and over Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biopsy Clinical trials Finasteride - therapeutic use General aspects Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical diagnosis Medical sciences Men Middle Aged Nephrology. Urinary tract diseases Prevalence Prostate - pathology Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - epidemiology Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Risk Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A11%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20Prostate%20Cancer%20among%20Men%20with%20a%20Prostate-Specific%20Antigen%20Level%20%E2%89%A44.0%20ng%20per%20Milliliter&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Thompson,%20Ian%20M&rft.date=2004-05-27&rft.volume=350&rft.issue=22&rft.spage=2239&rft.epage=2246&rft.pages=2239-2246&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa031918&rft_dat=%3Cproquest_cross%3E645396691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223941653&rft_id=info:pmid/15163773&rfr_iscdi=true |